Press release - 18/11/2021 Overcoming resistance to treatment for breast, bowel, and pancreatic cancer As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 24/02/2021 Disease progression in childhood cancer: Lengthening of telomeres promotes relapse Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes. https://www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
Press release - 15/11/2021 Using T cell to target malignant brain tumors Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
Press release - 23/06/2023 The molecular control centre of our protein factories Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
Press release - 08/01/2024 Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor. https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
Press release - 23/01/2025 ERC Funding for „EmbryoNet-AI“ Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform for the automated evaluation of experiments – for example, in drug development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-embryonet-ai
Press release - 11/02/2025 New perspectives for personalized therapy of brain tumors Scientists from the German Cancer Research Center (DKFZ) and ShanghaiTech University have developed an innovative method for growing brain tumors of individual patients in the laboratory that mimic the original structure and the molecular property of the parental tumor as closely as possible. Drug tests in this model were found to correlate very well with actual patient responses, making it a valuable method for investigating therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-perspectives-personalized-therapy-brain-tumors
Press release - 28/02/2025 Recognise developmental disorders early with AI: Automatically classifying movement patterns in babies Using a new combination of three sensors and artificial intelligence, researchers at Heidelberg Medical Faculty of Heidelberg University and Heidelberg University Hospital are recognising patterns in babies' movements that show whether their nervous system is developing healthily.https://www.gesundheitsindustrie-bw.de/en/article/press-release/recognise-developmental-disorders-early-ai-automatically-classifying-movement-patterns-babies
Press release - 14/07/2025 Faster and brighter protein labeling with new tool SNAP-tag2 The protein SNAP-tag is a powerful tool for labeling proteins with synthetic fluorophores for bioimaging. Scientists at the Max Planck Institute for Medical Research in Heidelberg have engineered a much improved version named SNAP-tag2 as well as optimized substrates for faster labeling in live cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/faster-and-brighter-protein-labeling-new-tool-snap-tag2
Dossier - 23/01/2012 The neurosciences In recent years, the neurosciences have increasingly made the leap from a purely basic science to applied research. Despite all this, basic research in south-west Germany is more diverse than ever. The discipline still has a number of breakthroughs to look forward to. The brain remains the most enigmatic human organ and one of the fascinating mysteries of the 21st century.https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-neurosciences
Press release - 29/11/2021 Tracking down resistant cancer cells In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
Press release - 13/06/2024 Position of the cell nucleus affects epigenetics and therefore gene activity and cell function Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
Press release - 05/11/2024 Heidelberg scientist receives highly endowed EC synergy grant Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-scientist-receives-highly-endowed-ec-synergy-grant
Press release - 11/07/2025 Cellular stress response – researchers discover potential therapeutic target for heart failure Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellular-stress-response-researchers-discover-potential-therapeutic-target-heart-failure
Press release - 19/02/2026 Seeing cells in a new light Illuminating the tiniest details of living cells just got a major boost: Scientists at the Max Planck Institute for Medical Research have developed new markers that glow in the far-red range and are activated by light. They are stable, easy to control, and compatible with several super-resolution microscopy techniques, as outlined in a paper published in the journal Chem.https://www.gesundheitsindustrie-bw.de/en/article/press-release/seeing-cells-new-light
Press release - 03/03/2021 New Baden-Württemberg network to reduce animal experiments A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
Press release - 30/09/2021 New microscopy technique makes deep in vivo brain imaging possible A pioneering technique developed by the Prevedel Group at EMBL allows neuroscientists to observe live neurons deep inside the brain – or any other cell hidden within an opaque tissue. The technique is based on two state-of-the-art microscopy methods, three-photon microscopy and adaptive optics. The paper reporting on this advancement was published on 30th September 2021 in Nature Methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-microscopy-technique-makes-deep-vivo-brain-imaging-possible
Press release - 28/09/2022 First successful trial for early detection of HPV-related cancer of the pharynx Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erste-erfolgreiche-studie-zur-frueherkennung-von-hpv-bedingtem-krebs-im-rachenraum
Press release - 12/09/2024 Power-to-vitamins: microbes produce folate from simple basic ingredients Biotechnology team at University of Tübingen obtains valuable byproduct in protein production. This could be a potential to the contribution of feeding a growing world population without livestock farming.https://www.gesundheitsindustrie-bw.de/en/article/press-release/power-vitamins-microbes-produce-folate-simple-basic-ingredients
Press release - 14/08/2025 Freezing brain tumor cells in a dormant state Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.https://www.gesundheitsindustrie-bw.de/en/article/press-release/freezing-brain-tumor-cells-dormant-state
Press release - 15/10/2025 NGS-based diagnostics for identifying sepsis pathogens wins EARTO Innovation Award A method developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB enables bacterial, viral, fungal, or parasitic pathogens in sepsis patients to be identified much faster than before and with the highest precision. The approach is based on high-throughput sequencing of cell-free DNA circulating in the blood and was honored with the EARTO Innovation Award in the "Impact Delivered" category on October 14,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ngs-based-diagnostics-identifying-sepsis-pathogens-wins-earto-innovation-award
Press release - 01/09/2025 Rare seasonal brain shrinkage in shrews is driven by water loss, not cell death Knowing how shrews loose brain volume over winter is the first step to understanding how they reverse this loss and regrow healthy brains in summer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-seasonal-brain-shrinkage-shrews-driven-water-loss-not-cell-death
Press release - 24/07/2025 Solutions that minimise clinical waste and maximise recycling How can the transformation to increase sustainability in hospitals succeed? Participants in the SustainMed project presented their answers at the closing event on 27 June 2025 in Stuttgart. The Ministry of the Environment, Climate Protection and the Energy Sector Baden-Württemberg provided approximately 500,000 euros in funding to develop solutions for goals such as reducing volumes of waste in hospitals.https://www.gesundheitsindustrie-bw.de/en/article/press-release/solutions-minimise-clinical-waste-and-maximise-recycling
Expert interview - 16/12/2024 Learning from Nature for Innovation Natural phenomena are used to find technological solutions in a number of fields. In an interview with BIOPRO, Prof. Dr. Peter M. Kunz discusses groundbreaking innovations emerging from Baden-Württemberg and shares insights on how the principles of bionics can inspire the next generation of innovators.https://www.gesundheitsindustrie-bw.de/en/article/news/learning-nature-innovation
Press release - 07/11/2025 How the biological clock ticks in the female reproductive tract - Breakthrough of the Year Award 2025 for Ângela Gonçalves Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging. The scientist from the DKFZ-Hector Cancer Institute is the winner of the Falling Walls Foundation's “Breakthrough of the Year 2025” award in the Women's Impact category.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-biological-clock-ticks-female-reproductive-tract-breakthrough-year-award-2025-angela-goncalves
Press release - 17/05/2023 Playing hide and seek in the centromere Centromeres, the DNA sections often found at the center of the chromosomes, display enormous interspecies diversity, despite having the same vital role during cell division across almost the entire tree of life. An international team of researchers has discovered that the variation in centromere DNA regions can be strikingly large even within a single species. The findings, now published in the journal Nature, shed light on the molecular…https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-hide-and-seek-centromere
Press release - 29/11/2023 Tracing the Evolution of the Cerebellum Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
Press release - 15/09/2025 How HIV enters the genome – Researchers identify previously unknown mechanism Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-hiv-enters-genome-researchers-identify-previously-unknown-mechanism
COVIC-19 clinical trial - 07/04/2022 Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.https://www.gesundheitsindustrie-bw.de/en/article/news/convalescent-plasma-covid-19-therapy-clinical-trial-should-bring-clarity
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 17/09/2024 Five new cross-border doctoral networks at Universität Heidelberg Five transnational and cross-institutional doctoral networks at Heidelberg University are being funded as part of the “Marie Skłodowska-Curie Actions”. They work together on current scientific topics with high innovation potential. Ruperto Carola coordinates an MSCA Doctoral Network on artificial intelligence in physics, two networks in medicine, life sciences and engineering. https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-new-cross-border-doctoral-networks-universitat-heidelberg
Press release - 11/01/2022 Obesity at a young age - a risk factor for early colorectal cancer The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/obesity-young-age-risk-factor-early-colorectal-cancer
Press release - 09/09/2022 Breaking down proteins: How starving cancer cells switch food sources Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team of scientists could identify the protein LYSET as part of a pathway that allows cancer cells to make this switch. Their findings are now published in the journal Science.https://www.gesundheitsindustrie-bw.de/en/article/press-release/neu-identifiziertes-protein-ermoeglicht-krebszellen-auf-alternative-nahrungsquellen-auszuweichen
Press release - 22/05/2024 Stretched beyond the limits of the cell: the molecular biomechanics of collagen Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stretched-beyond-limits-cell-molecular-biomechanics-collagen
Press release - 03/07/2024 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities
Press release - 29/08/2025 Sleeping beauties: the biology behind oocyte dormancy The maturation process of oocytes remains paused for several years. Researchers from Konstanz and Göttingen have now found out which protein ensures this state is maintained over such a long period.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sleeping-beauties-biology-behind-oocyte-dormancy
Press release - 23/09/2025 Not all ALK fusions act the same: Variants influence treatment success in lung cancer About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike. https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
Press release - 27/10/2025 Role of intestinal bacteria in the development of colorectal cancer: Emmy Noether grant for DKFZ researcher Jens Puschhof The German Research Foundation (DFG) is funding a new Emmy Noether project led by Jens Puschhof from the German Cancer Research Center (DKFZ). With this project, the junior researcher aims to decipher the role of certain intestinal bacteria in the earliest stages of colorectal cancer development and investigate how this process can be halted. The long-term goal is to develop new preventive strategies against colorectal cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/role-intestinal-bacteria-development-colorectal-cancer-emmy-noether-grant-dkfz-researcher-jens-puschhof
Press release - 21/11/2025 How mitochondria influence mental health Hans Kupczyk visiting professorship for Professor Martin Picard He researches stress and ageing at the interface of psychology and biology and is a guest at Ulm University: Professor Martin Picard from Columbia University has been awarded the Hans Kupczyk Visiting Professorship 2025, which is based in the Department of Clinical and Biological Psychology this year. On the occasion of the awarding of the visiting professorship, Picard spoke about energy as the foundation of human health of body and mind.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-mitochondria-influence-mental-health-hans-kupczyk-visiting-professorship-professor-martin-picard
Press release - 24/11/2025 Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
Neurosciences - 28/02/2024 Mesh microelectrode arrays: research with brain organoids on a new level How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.https://www.gesundheitsindustrie-bw.de/en/article/news/mesh-microelectrode-arrays-research-brain-organoids-new-level
Macrophages interacting with cytomegaloviruses - 22/02/2022 Cytomegaloviruses subvert macrophage identity Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
Press release - 06/01/2023 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-positive-data-joint-covid-19-and-flu-mrna-vaccine-development-programs
Press release - 04/03/2024 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum valuehttps://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million
Press release - 07/05/2024 Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
Life-saving smartphone app delivers rapid help during cardiac arrest - 19/05/2025 Do smartphone-based first responder alerting systems increase the chances of survival in the event of cardiac arrest? Every minute counts when the heart suddenly stops beating or pumps so weakly that the brain is no longer receiving enough oxygen. The HEROES trial, coordinated in Freiburg, is investigating whether the survival rate of patients requiring out-of-hospital resuscitation improves when qualified first responders are alerted via the ‘Region of Lifesavers’ app - enabling them to begin high-quality resuscitation measures as early as possible.https://www.gesundheitsindustrie-bw.de/en/article/news/do-smartphone-based-first-responder-alerting-systems-increase-chances-survival-event-cardiac-arrest
Press release - 02/08/2023 Freiburg research team casts light on signal-dependent formation of mitochondria Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria. https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden